TransCelerate Study Reveals One-Third of Clinical Trial Procedures Are Non-Essential, Proposes Streamlined Data Collection Framework

TransCelerate BioPharma (搜索)搜索该词条 and the Tufts Center for the Study of Drug Development (搜索)搜索该词条 have published groundbreaking research revealing significant inefficiencies in clinical trial data collection, with nearly one-third of study procedures failing to support primary endpoints or being conducted more frequently than necessary. The peer-reviewed study, published in Therapeutic Innovation & Regulatory Science, provides the first comprehensive benchmarking analysis of phase II and III protocol procedures and offers a roadmap for more streamlined, patient-centric trial designs.

Massive Data Growth Reveals Systemic Inefficiencies

The collaborative research demonstrates the dramatic expansion of clinical trial complexity, with Phase III protocols now averaging 5.96 million data points. Despite this exponential growth in data volume, the analysis reveals that almost one-third of study procedures do not support primary, key secondary and safety endpoints or were conducted more times than necessary.

"The preprint version of the manuscript and recent conference presentations have generated very strong positive responses to the results and insights from this collaborative research study," said Kenneth Getz, Executive Director of Tufts CSDD and lead author. "We're delighted that the final published manuscript is now available and hope that the benchmarks and insights from the study will reach an even larger audience."

Impact on Participants and Research Sites

The study identifies that non-core and non-essential procedures contribute substantially to participant and site burden while adding operational complexity without advancing the study's main objectives and outcomes. This finding has significant implications for patient retention, site engagement, and overall trial efficiency in an increasingly competitive clinical research environment.

The research assesses how protocol design practices have evolved and identifies specific areas where sponsors may be able to reduce scientific and operational complexity while lowering participant and site burden. The peer-reviewed manuscript outlines where inefficiencies originate and offers practical considerations for modernizing protocol design.

Alignment with Regulatory Guidelines

The findings align with ICH E6(R3) guidelines, which encourage fit-for-purpose data collection to reduce unnecessary complexity and burden while maintaining trial quality. The study provides sponsors with evidence-based strategies to implement these regulatory recommendations effectively.

TransCelerate's Optimizing Data Collection team is advancing tools and frameworks to help R&D organizations assess the scientific, regulatory, and operational utility of the data they collect. The goal isn't to eliminate entire categories of data collection, but to ensure every data point meaningfully advances scientific, regulatory, or patient-centered objectives.

Future Development and Stakeholder Collaboration

The organization plans to collaborate with patient groups, sites, and other stakeholders to further refine and develop these tools, ensuring they reflect diverse perspectives and real-world needs. These resources are designed to help sponsors assess not just how much data is collected, but why it is collected, ensuring that each data element contributes effectively to scientific, regulatory, or patient-centric goals.

The publication represents the peer-reviewed, final version of analysis previously shared as a pre-print, marking the latest milestone in efforts to help the biopharmaceutical industry better understand and address the growing complexity of clinical trial data collection.